Review
Oncology
Shipra Singhal, Priyal Maheshwari, Praveen Thaggikuppe Krishnamurthy, Vaishali M. Patil
Summary: Drug repurposing is an effective approach to repurpose clinically approved noncancer drugs with known targets for the treatment of cancer. Various types of noncancer drugs have shown promising outcomes in preclinical and clinical phases.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
(2022)
Review
Biochemistry & Molecular Biology
Tania Lourenco, Nuno Vale
Summary: Prostate cancer is the second most common cancer in men worldwide and a leading cause of death. Standard treatments face issues like side effects and resistance, highlighting the need for drugs that can fill these gaps. This review compiles drugs that can be repurposed for prostate cancer treatment, categorizing them based on their pharmacotherapeutic groups and discussing their mechanisms of action.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Medicine, Research & Experimental
Sandipan Datta, Thomas Sears, Gino Cortopassi, Kevin Woolard, James M. Angelastro
Summary: GBM tumors contain glioma stem-like cells (GSCs) and differentiated GBM cells (d-GCs) with differences in mitochondrial metabolism. Inhibiting mitochondrial function selectively targets GSCs and may offer a potential therapeutic option for GBM treatment. Further studies are needed to explore the effectiveness of mitochondrial inhibitors as a targeted therapy for GBM.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Review
Multidisciplinary Sciences
Ningna Weng, Zhe Zhang, Yunhan Tan, Xiaoyue Zhang, Xiawei Wei, Qing Zhu
Summary: This article summarizes the background, aim, and key scientific concepts of repurposing antifungal drugs for cancer therapy, and discusses the challenges and perspectives for their future development and clinical applications.
JOURNAL OF ADVANCED RESEARCH
(2023)
Article
Oncology
Mark P. Lythgoe, Vinay Prasad
Summary: Canakinumab, an anti-interleukin-1 beta monoclonal antibody, has been approved for the treatment of immune-related disorders. It has shown potential in reducing the occurrence and mortality of lung cancer, leading to further clinical trials. However, the initial trials targeting cancer have not met their primary efficacy endpoints.
BRITISH JOURNAL OF CANCER
(2022)
Article
Biology
Sita Sirisha Madugula, Lijo John, Selvaraman Nagamani, Anamika Singh Gaur, Vladimir V. Poroikov, G. Narahari Sastry
Summary: Machine learning and SAR analysis were used in this study to identify new indications for approved drugs, generating novel insights through clustering patterns.
COMPUTERS IN BIOLOGY AND MEDICINE
(2021)
Review
Pharmacology & Pharmacy
U. Jisha Pillai, Anindita Ray, Meenu Maan, Mainak Dutta
Summary: The identification of new drugs for cancer treatment faces hurdles, leading to an increasing interest in drug repurposing, which involves using old drugs for new therapeutic purposes. This approach is cost-effective and enables fast clinical translation. As cancer is also considered a metabolic disease, drugs approved for metabolic disorders, such as diabetes and cardiovascular disease (CVD), are being actively repurposed for anticancer treatment. This review discusses the repurposing of these drugs and highlights their targeting of cancer signaling pathways.
DRUG DISCOVERY TODAY
(2023)
Review
Medicine, Research & Experimental
Roohi Mohi-ud-din, Apporva Chawla, Pooja Sharma, Prince Ahad Mir, Faheem Hyder Potoo, Zeljko Reiner, Ivan Reiner, Dilek Arslan Atessahin, Javad Sharifi-Rad, Reyaz Hassan Mir, Daniela Calina
Summary: Cancer is a significant global health challenge, and the high cost and lengthy process of developing new anti-cancer drugs hinder progress in cancer treatment. Therefore, repurposing approved non-oncology drugs as alternative options for cancer treatment has the potential to be effective and cost-efficient.
EUROPEAN JOURNAL OF MEDICAL RESEARCH
(2023)
Review
Neurosciences
Alessandra Rufini, Florence Malisan, Ivano Condo, Roberto Testi
Summary: Friedreich ataxia is a rare neurodegenerative disorder caused by insufficient levels of the essential mitochondrial protein frataxin. It leads to reduced activity of mitochondrial enzymes, impaired mitochondrial metabolism, reduced ATP production and inefficient anti-oxidant response, resulting in the progressive loss of movement coordination and daily activity performance. Drug repositioning is a viable alternative for identifying a therapy for Friedreich ataxia.
FRONTIERS IN NEUROSCIENCE
(2022)
Article
Chemistry, Medicinal
Saghir Ali, Jia Zhou
Summary: The objective of this review is to provide an update on fluorine-containing drugs approved by the FDA in the past five years. A total of fifty-eight fluorinated entities were accepted for the diagnosis, mitigation, and treatment of various diseases. The drugs are categorized based on their therapeutic areas and information about their trade name, approval date, active ingredients, developers, indications, and mechanisms of action are provided. This review is expected to inspire drug discovery and medicinal chemistry research in both industrial and academic settings, leading to the discovery of new drugs in the future.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Chemistry, Multidisciplinary
Bram Bogaert, Felix Sauvage, Roberta Guagliardo, Cristina Muntean, Van Phuc Nguyen, Eline Pottie, Mike Wels, An-Katrien Minnaert, Riet De Rycke, Qiangbing Yang, Dan Peer, Niek Sanders, Katrien Remaut, Yannis M. Paulus, Christophe Stove, Stefaan C. De Smedt, Koen Raemdonck
Summary: With the recent clinical approval of siRNA-based drugs and COVID-19 mRNA vaccines, the potential of RNA therapeutics has gained widespread acceptance. Researchers have developed a novel type of lipid-based nanocarrier called CADosomes, which can efficiently deliver mRNA to target cells and have shown promising results in both in vitro and in vivo studies. This versatile and straightforward approach has the potential to revolutionize drug combination therapies.
JOURNAL OF CONTROLLED RELEASE
(2022)
Review
Pharmacology & Pharmacy
Vigneshwaran Namasivayam, Senthikumar Palaniappan, Murugesan Vanangamudi
Summary: Researchers face challenges in developing treatments for emerging and re-emerging epidemic infections. Drug repurposing is a reliable strategy for discovering new antiviral agents quickly and reducing the need for clinical trials.
DRUG DISCOVERY TODAY
(2022)
Review
Medicine, Research & Experimental
Ademola C. Famurewa, Anirban Goutam Mukherjee, Uddesh Ramesh Wanjari, Aarthi Sukumar, Reshma Murali, Kaviyarasi Renu, Balachandar Vellingiri, Abhijit Dey, Abilash Valsala Gopalakrishnan
Summary: Platinum-based anticancer drugs have been widely used for treating various cancer types, but their toxicity to non-targeted organs is a concern. Research has shown that this toxicity is associated with free radical generation, DNA impairment, mitochondrial dysfunctions, and other factors. Repurposing non-anticancer drugs has emerged as a strategy to mitigate the side effects of platinum-based drugs.
Review
Biochemistry & Molecular Biology
Rafaela Rodrigues, Diana Duarte, Nuno Vale
Summary: Cancer is a leading cause of death worldwide, with breast cancer being the most prevalent type in women. Drug resistance poses a major challenge in breast cancer treatment, leading to high mortality rates. Repurposing drugs and conducting further research and clinical trials are important for improving the effectiveness and personalization of breast cancer treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Medicine, Research & Experimental
Yue Huang, Jessica C. Hsu, Hyun Koo, David P. Cormode
Summary: Ferumoxytol is an intravenous iron oxide nanoparticle formulation that has potential for various biomedical applications due to its excellent physical properties. It has been extensively used in preclinical and clinical studies for diagnostic, therapeutic, and theranostic purposes.
Article
Biochemistry & Molecular Biology
Feiran Li, Yu Chen, Mihail Anton, Jens Nielsen
Summary: Enzyme parameters are crucial for understanding, modeling, and engineering cells. Experimental measurements only cover a small portion of enzyme-compound pairs, and even less in non-model organisms. Artificial intelligence techniques have accelerated the exploration of enzyme properties by predicting them in a high-throughput manner. GotEnzymes is a comprehensive database that provides predicted enzyme parameters using AI approaches, allowing for interactive web exploration and programmatic access.
NUCLEIC ACIDS RESEARCH
(2023)
Editorial Material
Biotechnology & Applied Microbiology
Gen Zou, Jens B. Nielsen, Yongjun Wei
Summary: Recent advances in synthetic biology have revolutionized mushroom farming by shifting the focus from traditional cultivation to comprehensive applications using cutting-edge biotechnologies. Promising applications in this field include precision breeding, exploration of biosynthetic gene clusters, development of mushroom chassis cells, and construction of cell factories for high-value products.
TRENDS IN BIOTECHNOLOGY
(2023)
Article
Chemistry, Medicinal
Amalyn Nain-Perez, Oscar Nilsson, Aleksei Lulla, Liliana Haversen, Paul Brear, Sara Liljenberg, Marko Hyvonen, Jan Boren, Morten Grotli
Summary: This study describes a novel series of PKL modulators that can allosterically activate or inhibit the enzyme. These modulators were assessed for their effect on PKL activity using liver cell lysates. The study identified compounds that significantly increased PKL activity, as well as compounds that inhibited its activity. Crystal structures provided insights into the conformations of these modulators, which can be used as a reference for designing new modulators.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Biotechnology & Applied Microbiology
Rosa Lundbye Allesoe, Agnete Troen Lundgaard, Ricardo Hernandez Medina, Alejandro Aguayo-Orozco, Joachim Johansen, Jakob Nybo Nissen, Caroline Brorsson, Gianluca Mazzoni, Lili Niu, Jorge Hernansanz Biel, Valentas Brasas, Henry Webel, Michael Eriksen Benros, Anders Gorm Pedersen, Piotr Jaroslaw Chmura, Ulrik Plesner Jacobsen, Andrea Mari, Robert Koivula, Anubha Mahajan, Ana Vinuela, Juan Fernandez Tajes, Sapna Sharma, Mark Haid, Mun-Gwan Hong, Petra B. Musholt, Federico De Masi, Josef Vogt, Helle Krogh Pedersen, Valborg Gudmundsdottir, Angus Jones, Gwen Kennedy, Jimmy Bell, E. Louise Thomas, Gary Frost, Henrik Thomsen, Elizaveta Hansen, Tue Haldor Hansen, Henrik Vestergaard, Mirthe Muilwijk, Marieke T. Blom, Leen M. T. Hart, Francois Pattou, Violeta Raverdy, Soren Brage, Tarja Kokkola, Alison Heggie, Donna McEvoy, Miranda Mourby, Jane Kaye, Andrew Hattersley, Timothy McDonald, Martin Ridderstrale, Mark Walker, Ian Forgie, Giuseppe N. Giordano, Imre Pavo, Hartmut Ruetten, Oluf Pedersen, Torben Hansen, Emmanouil Dermitzakis, Paul W. Franks, Jochen M. Schwenk, Jerzy Adamski, Mark McCarthy, Ewan Pearson, Karina Banasik, Simon Rasmussen, Soren Brunak
Summary: The application of multiple omics technologies in biomedical cohorts can reveal patient-level disease characteristics and individualized response to treatment. We developed a deep-learning-based framework, MOVE, to integrate and analyze multi-omics data from a cohort of newly diagnosed type 2 diabetes patients. By using in silico perturbations, we identified drug-omics associations in the multi-modal datasets with higher sensitivity than univariate statistical tests.
NATURE BIOTECHNOLOGY
(2023)
Article
Nutrition & Dietetics
Umberto Maria Battisti, Chunixa Gao, Fady Akladios, Woonghee Kim, Hong Yang, Cemil Bayram, Ismail Bolat, Metin Kiliclioglu, Nursena Yuksel, Ozlem Ozdemir Tozlu, Cheng Zhang, Jihad Sebhaoui, Shazia Iqbal, Saeed Shoaie, Ahmet Hacimuftuoglu, Serkan Yildirim, Hasan Turkez, Mathias Uhlen, Jan Boren, Adil Mardinoglu, Morten Grotli
Summary: This study presents a new finding that ellagic acid and its derivatives can selectively and potently inhibit liver pyruvate kinase, which may open up new therapeutic options for non-alcoholic fatty liver disease (NAFLD).
Article
Neurosciences
Burak Yulug, Ozlem Altay, Xiangyu Li, Lutfu Hanoglu, Seyda Cankaya, Simon Lam, Halil Aziz Velioglu, Hong Yang, Ebru Coskun, Ezgi Idil, Rahim Nogaylar, Ahmet Ozsimsek, Cemil Bayram, Ismail Bolat, Sena Oner, Ozlem Ozdemir Tozlu, Mehmet Enes Arslan, Ahmet Hacimuftuoglu, Serkan Yildirim, Muhammad Arif, Saeed Shoaie, Cheng Zhang, Jens Nielsen, Hasan Turkez, Jan Boren, Mathias Uhlen, Adil Mardinoglu
Summary: A clinical trial was conducted to study the effect of combined metabolic activators (CMA) on Alzheimer's disease (AD) patients. The results showed that CMA can improve cognitive functions and clinical parameters associated with AD. This study provides evidence for the use of CMA in the treatment of AD.
TRANSLATIONAL NEURODEGENERATION
(2023)
Article
Multidisciplinary Sciences
Leo Dahl, Ilana B. Kotliar, Annika Bendes, Tea Dodig-Crnkovic, Samuel Fromm, Arne Elofsson, Mathias Uhlen, Thomas P. Sakmar, Jochen M. Schwenk
Summary: A multiplexed immunoassay was developed to test the selectivity of over 400 anti-GPCR antibodies. The results showed that about 61% of the antibodies were selective, 11% bound off-target, and 28% did not bind to any GPCR. It was also found that on-target antibodies had longer, more disordered antigens and were less buried in the interior of GPCR proteins compared to other antibodies.
Article
Chemistry, Medicinal
Umberto Maria Battisti, Leticia Monjas, Fady Akladios, Josipa Matic, Eric Andresen, Carolin H. Nagel, Malin Hagkvist, Liliana Haversen, Woonghee Kim, Mathias Uhlen, Jan Boren, Adil Mardinoglu, Morten Grotli
Summary: The inhibition of liver pyruvate kinase is a potential strategy for treating or reversing non-alcoholic fatty liver disease (NAFLD). Urolithin C has been identified as a promising scaffold for developing allosteric inhibitors of liver pyruvate kinase. A comprehensive structure-activity analysis of urolithin C and its analogues was conducted, revealing important chemical features for the desired activity. These findings may facilitate the discovery of more potent and selective PKL allosteric inhibitors.
Editorial Material
Endocrinology & Metabolism
Hong Yang, Cheng Zhang, Hasan Turkez, Mathias Uhlen, Jan Boren, Adil Mardinoglu
Article
Chemistry, Physical
Carlos Benitez-Martin, Jean Rouillon, Morten Grotli, Joakim Andreasson
Summary: We present a tri-component photochromic molecular cocktail that can encrypt and decrypt information. The cocktail exhibits a highly non-linear fluorescent response to inputs, enabling the generation of encryption keys. The all-optical system can produce over 80 million unique fluorescence responses by applying different input combinations, and can be operated using a conventional fluorimeter.
Article
Biotechnology & Applied Microbiology
Hulya Gundesli, Medi Kori, Kazim Yalcin Arga
Summary: This study identifies dysregulation of several PLEC isoforms in different cancer types and stages, and highlights PLEC 1d and PLEC 1f as potential biomarkers for early cancer detection. Further functional studies are needed to uncover the role of plectin isoforms in cancer development and guide the development of novel cancer therapeutics.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY
(2023)
Letter
Biotechnology & Applied Microbiology
Ceyda Kula, Kazim Yalcin Arga
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY
(2023)
Article
Biotechnology & Applied Microbiology
Elif Kubat Oktem, Busra Aydin, Gizem Gulfidan, Kazim Yalcin Arga
Summary: Cancer and arachidonic acid (AA) are closely linked, with AA metabolites regulating several critical functions associated with carcinogenesis. This study analyzed transcriptome data from 12 different cancer types and identified 77 differentially expressed AAP gene signatures and 37 associated metabolites. These findings provide potential therapeutic and diagnostic targets for precision/personalized medicine in oncology.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY
(2023)
Article
Biotechnology & Applied Microbiology
Onur Erdogan, Seyma Colakoglu Ozkaya, Can Erzik, Kaya Bilguvar, Kazim Yalcin Arga, Fatih Bayrakli
Summary: Precision/personalized medicine in oncology, particularly in glioblastoma, holds great promise for improving treatment options and outcomes for patients through molecular profiling and personalized reporting.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY
(2023)